Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer

Sponsor
Fudan University
Study ID
NCT06196671
Phase
PHASE2
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • H101 — DRUG
    H101 15x10\^11vp intratumorally injection starts at day 1.
  • Camrelizumab — DRUG
    Camrelizumab will be administered at 200 mg i.v. every 3 weeks at day 2.

Study Details

The purpose of this study is to evaluate the efficacy of oncolytic virus plus PD-1 inhibitor to Patients with Advanced Pancreatic Cancer.

Key Dates

Start date
Dec 1, 2026
Status verified
Mar 2025
Primary completion
Jan 1, 2028
Completion
Jan 1, 2028

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Oncolytic virus plus PD-1 inhibitor
    * H101 intratumorally injection starts at day 1. * Camrelizumab will be administered at 200 mg i.v. every 3 weeks at day 2. * After two cycles of treatment, Camrelizumab will be administered alone at 200 mg i.v. every 3 weeks from cycle 3 until documented disease progression, development of unacceptable toxicity, participant request, or withdrawal of consent. * The following treatment will be applied according to the newest edition of National Comprehensive Cancer Network (NCCN) guideline.

Primary Outcome Measure

Overall survival，OS [ Time Frame: At the end of Cycle 1 (each cycle is 21 days) ]

Central Contacts

Related Studies